7307139
COCORO

Cognitive Genetics Collaborative Research Organization
EGUIDE42131301311303030

1171301308130451271813016

COCOROCOCORO
2000

WAIS
Japanese Adult Reading Test (JART)Sumiyoshi et al Sczophrenia Res

2018

101

3280
1q21
Morita et al

3

Schizophrenia Res

20q13

122018; Kikuchi et al

Sci Rep

2018

FreeSurfer
Koshiyama et al Schizophrenia Res
2018

Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)
Kudo et al Int

J Neuropsychopharmacol 2018

ENIGMAFreeSurfer

9572
van Erp

Biological Psychiatry

2018

EGUIDEEGUIDE

201642EGUIDE

131

20
1200
EGUIDE

4423

EGUIDE

Quality Indicator: QI
QI

EBMMinds

102

(1)

(2)
EGUIDEEGUIDE30
2720020(3)
(4)
13(5)
(6)

(1)
1)

Miki K, Nakae A, Shi K, Yasuda Y, Yamamori H, Fujimoto M, Ikeda M, Shibata M, Yukioka
M, Hashimoto R: Frequency of mental disorders among chronic pain patients with orwithout fibromyalgia in Japan. Neuropsychopharmacol Rep 38(4): 167-174, 2018.

2)

Koshiyama D, Fukunaga M, Okada N, Morita K, Nemoto K, Yamashita F, Yamamori H,Yasuda Y, Fujimoto M, Kelly S, Jahanshad N, Kudo N, Azechi H, Watanabe Y, Donohoe G,103

32Thompson PM, Kasai K, Hashimoto R: Role of frontal white matter and corpus callosum onsocial function in schizophrenia. Schizophr Res 202: 180-187, 2018.
3)

Morita K, Miura K, Fujimoto M, Shishido E, Shiino T, Takahashi J, Yamamori H, Yasuda
Y, Kudo N, Hirano Y, Koshiyama D, Okada N, Ikeda M, Onitsuka T, Ozaki N, Kasai K,Hashimoto R: Abnormalities of eye movement are associated with work hours inschizophrenia. Schizophr Res 202:420-422, 2018.

4)

Sumiyoshi C, Fujino H, Yamamori H, Kudo N, Azechi H, Fujimoto M, Yasuda Y, Ohi K,Sumiyoshi T, Hashimoto R: Predicting work outcome in patients with schizophrenia:
Influence of IQ decline. Schizophr Res 201: 172-179, 2018.

5)

van Erp TGM, Walton E, Hibar DP, Schmaal L, Jiang W, Glahn DC, Pearlson GD, Yao N,Fukunaga M, Hashimoto R,(17810) Okada N, Yamamori H, Bustillo JR, ClarkVP, Agartz I, Mueller BA, Cahn W, de Zwarte SMC, Hulshoff Pol HE, Kahn RS, Ophoff RA,van Haren NEM, Andreassen OA, Dale AM, Doan NT, Gurholt TP, Hartberg CB, Haukvik
UK, Jørgensen KN, Lagerberg TV, Melle I, Westlye LT, Gruber O, Kraemer B, Richter A,Zilles D, Calhoun VD, Crespo-Facorro B, Roiz-Santiañez R, Tordesillas-Gutiérrez D,Loughland C, Carr VJ, Catts S, Cropley VL, Fullerton JM, Green MJ, Henskens FA,Jablensky A, Lenroot RK, Mowry BJ, Michie PT, Pantelis C, Quidé Y, Schall U, Scott RJ,Cairns MJ, Seal M, Tooney PA, Rasser PE, Cooper G, Shannon Weickert C, Weickert TW,Morris DW, Hong E, Kochunov P, Beard LM, Gur RE, Gur RC, Satterthwaite TD, Wolf DH,Belger A, Brown GG, Ford JM, Macciardi F, Mathalon DH, O'Leary DS, Potkin SG, Preda
A, Voyvodic J, Lim KO, McEwen S, Yang F, Tan Y, Tan S, Wang Z, Fan F, Chen J, Xiang H,Tang S, Guo H, Wan P, Wei D, Bockholt HJ, Ehrlich S, Wolthusen RPF, King MD,Shoemaker JM, Sponheim SR, De Haan L, Koenders L, Machielsen MW, van Amelsvoort T,Veltman DJ, Assogna F, Banaj N, de Rossi P, Iorio M, Piras F, Spalletta G, McKenna PJ,Pomarol-Clotet E, Salvador R, Corvin A, Donohoe G, Kelly S, Whelan CD, Dickie EW,Rotenberg D, Voineskos AN, Ciufolini S, Radua J, Dazzan P, Murray R, Reis Marques T,Simmons A, Borgwardt S, Egloff L, Harrisberger F, Riecher-Rössler A, Smieskova R, Alpert
KI, Wang L, Jönsson EG, Koops S, Sommer IEC, Bertolino A, Bonvino A, Di Giorgio A,Neilson E, Mayer AR, Stephen JM, Kwon JS, Yun JY, Cannon DM, McDonald C, Lebedeva
I, Tomyshev AS, Akhadov T, Kaleda V, Fatouros-Bergman H, Flyckt L; Karolinska
Schizophrenia Project, Busatto GF, Rosa PGP, Serpa MH, Zanetti MV, Hoschl C, Skoch A,Spaniel F, Tomecek D, Hagenaars SP, McIntosh AM, Whalley HC, Lawrie SM, Knöchel C,Oertel-Knöchel V, Stäblein M, Howells FM, Stein DJ, Temmingh HS, Uhlmann A, LopezJaramillo C, Dima D, McMahon A, Faskowitz JI, Gutman BA, Jahanshad N, Thompson PM,Turner JA: Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098
Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis(ENIGMA) Consortium. Biol Psychiatry 84(9): 644-654, 2018.

6)

Kushima I, Aleksic B, Nakatochi M, Shimamura T, Okada T, Uno Y, Morikawa M, Ishizuka
K, Shiino T, Kimura H, Arioka Y, Yoshimi A, Takasaki Y, Yu Y, Nakamura Y, Yamamoto M,Iidaka T, Iritani S, Inada T, Ogawa N, Shishido E, Torii Y, Kawano N, Omura Y, Yoshikawa
T, Uchiyama T, Yamamoto T, Ikeda M, Hashimoto R,(8029) Yamamori H, Yasuda
Y, Someya T, Watanabe Y, Egawa J, Nunokawa A, Itokawa M, Arai M, Miyashita M, Kobori
A, Suzuki M, Takahashi T, Usami M, Kodaira M, Watanabe K, Sasaki T, Kuwabara H,Tochigi M, Nishimura F, Yamasue H, Eriguchi Y, Benner S, Kojima M, Yassin W, Munesue
T, Yokoyama S, Kimura R, Funabiki Y, Kosaka H, Ishitobi M, Ohmori T, Numata S,
Yoshikawa T, Toyota T, Yamakawa K, Suzuki T, Inoue Y, Nakaoka K, Goto YI, Inagaki M,104

Hashimoto N, Kusumi I, Son S, Murai T, Ikegame T, Okada N, Kasai K, Kunimoto S, MoriD, Iwata N, Ozaki N: Comparative Analyses of Copy-Number Variation in Autism Spectrum
Disorder and Schizophrenia Reveal Etiological Overlap and Biological Insights. Cell Rep
24(11): 2838-2856, 2018.
7)

Zhang Y, Hishimoto A, Otsuka I, Watanabe Y, Numata S, Yamamori H, Boku S, Horai T,
Someya T, Ohmori T, Hashimoto R, Sora I: Longer telomeres in elderly schizophrenia areassociated with long-term hospitalization in the Japanese population. J Psychiatr Res 103:161-166, 2018.

8)

Kikuchi M, Miura K, Morita K, Yamamori H, Fujimoto M, Ikeda M, Yasuda Y, Nakaya A,Hashimoto R: Genome-wide Association Analysis of Eye Movement Dysfunction inSchizophrenia. Sci Rep 8(1): 12347, 2018.

9)

Kudo N, Yamamori H, Ishima T, Nemoto K, Yasuda Y, Fujimoto M, Azechi H, Niitsu T,Numata S, Ikeda M, Iyo M, Ohmori T, Fukunaga M, Watanabe Y, Hashimoto K, Hashimoto
R: Plasma Levels of Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2) Are Associatedwith Hippocampal Volume and Cognitive Performance in Patients with Schizophrenia. Int
J Neuropsychopharmacol 21(7): 631-639, 2018.

10) Hibar DP, Cheung JW, Medland SE, Mufford MS, Jahanshad N, Dalvie S, Ramesar R,Stewart E, van den Heuvel OA, Pauls DL, Knowles JA, Stein DJ, Thompson PM, Enhancing
Neuro Imaging Genetics through Meta Analysis (ENIGMA) Consortium, International
Obsessive

Compulsive

DisorderFoundation

Genetics

Collaborative(IOCDF-GC):

Significant concordance of genetic variation that increases both the risk for obsessivecompulsive disorder and the volumes of the nucleus accumbens and putamen. Br J
Psychiatry 213(1): 430-436, 2018.
11) Ohi K, Sumiyoshi C, Fujino H, Yasuda Y, Yamamori H, Fujimoto M, Shiino T, Sumiyoshi T,Hashimoto R: Genetic Overlap between General Cognitive Function and Schizophrenia: A
Review of Cognitive GWASs. Int J Mol Sci 19(12): 3822, 2018.
12) Numata S, Umehara H, Ohmori T, Hashimoto R: Clozapine Pharmacogenetic Studies in
Schizophrenia: Efficacy and Agranulocytosis. Front Pharmacol 9: 1049, 2018.
13)
54(7)

835-840

2018

(2)
1)

2(2)

68-69

-20192)

Conference Report:(CINP)

Legato 4(3)50-523120183)
12(11)

26-27 20184)
5)

clozapine
EGUIDE

1451-1458

2018

Depression Strategy
8(3)

6)

21(11)

4-7

2018
33(1)

45-51

2018

(3)
1)
105

322018(4)
1)

EGUIDE30
H29-2)

--001

2019

EGUIDE
H29
H29-

H30--001

20193)

H30

20184)

2019

H30
201820195)
H30
coproduction

201820196)

H30
201820197)

H30

2018

20198)

H30
MRI
2018
2019

(5)
(6)
1)

15
CONSONANCE
69

106

2-3

2019

2019 WINTER

(1)
1)

,,,,

Hashimoto R: Behavior/Self-Reports/Paradigms based on RDoC focusing on cognitive
impairment, Symposium, WFSBP Asia Pacific Regional Congress of Biological Psychiatry(WFSBP 2018 KOBE), Hyogo, 2018.9.9.

2)

Okada N, Hashimoto R, Ozaki N, Kasai K: Circuits/Physiology biomarkers based on RDoC.
Symposium, WFSBP Asia Pacific Regional Congress of Biological Psychiatry (WFSBP 2018
KOBE), Hyogo, 2018.9.9.

3)

Hashimoto R: Cross-disorder analysis of neuroimaging data in Psychiatry, Japan-UK
Neuroscience Symposium 2019, Chiba, 2019.2.10.

4)
iPS20182018.8.25.

5)40612018.9.8.
6)

40
61

2018.9.8.

7)-2

2018.9.16.
8)72018.10.5.

9)
25in

2018.10.26.
10)
10

2018.9.30.

11)

iPS
2848

2018.11.15.
12)

2848

2018.11.15.

13)

28
48

2018.11.15.

14)
11

2018.12.2.

(2)
1)

Matsumura K, Nakazawa T, Okada S, Nagayasu K, Miura H, Kasai A, Takuma K,Yamamori H, Yasuda Y, Hashimoto R, Hashimoto H: The de novo Q1042R POGZ mutationin sporadic ASD disrupts the neuronal differentiation. 18th World Congress of Basic andClinical Pharmacology (WCP2018 Kyoto), Kyoto, 2018.7.5.

2)

Morita K, Miura K, Fujimoto M, Shishido E, Shiino T, Takahashi J, Yamamori H, Yasuda Y,Kudo N, Hirano Y, Koshiyama D, Okada N, Ikeda M, Onitsuka T, Ozaki N, Kasai K,Hashimoto R: Abnormalities of eye movement are associated with work hours in107

32

schizophrenia: A multi-site study. 7th BESETO International Psychiatry Conference, Seoul,
2018.9.15.
3)

Pisanu C, Akula N, Consortium on Lithium Genetics, Zompo M.D., Squassina A, McMahon
F.J: Integrative analysis of omics summary data to identify genes associated with lithium
response and related phenotypes in patients with bipolar disorder. 26th WCPG (WorldCongress of Psychiatric Genetics), Glasgow, 2018.10.14.

4)

Takahashi J, Miura K, Morita K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Shishido E,
Okazaki K, Shiino T, Kasai K, Hirano Y, Hashimoto R, Onitsuka T: Eye Movement
Abnormalities in Major Depressive Disorder. The 21 st Annual ISBD Conference(International Society for Bipolar Disorders), Sydney, 2019.3.21.

5)

Morita K, Miura K, Fujimoto M, Yamamori H, Yasuda Y, Kudo N, Azehi H, Okada N,Koshiyama D, Kawakami S, Morita S, Ikeda M, Kasai K, Hashimoto R: Eyemovement
abnormalities and their association with cognitive impairments in schizophrenia.
41
2018.7.26-28.

6)Takamura T, Nakamura T, Yoshinaga K, Ogata Y, Ozaki N, Kasai K, Hashimoto R,Hanakawa T: Resting-state functional connectivity MRI classification of major depressive
disorder in multi-site data.
41
2018.7.26-28.

7)
28
15

EGUIDE2018.7.28.

8)
EGUIDE15

2018.7.28.

9)15
2018.7.28.
10)
2018.9.5.
11)
40
61

2018.9.6.

12) Morita K, Miura K, Fujimoto M, Shishido E, Shiino T, Takahashi J, Yamamori H, Yasuda Y,Kudo N, Hirano Y, Koshiyama D, Okada N, Ikeda M, Onitsuka T, Ozaki N, Kasai K,Hashimoto R: Abnormalities of eye movement are associated with work hours inschizophrenia.
40
612018.9.6.
13) Takahashi J, Miura K, Morita K, Fujimoto M, Yamamori H, Yuka Y, Kudo N, Shishido E,Okazaki K, Kasai K, Hirano Y, Hashimoto R, Onitsuka T: Eye Movement Abnormalities inMajor Depressive Disorder.
4061
2018.9.7.
14)232018.10.18.

15)
28
10848

2018.11.14.16)
localconnectometry

2848

2018.11.14.
17)
2848

2018.11.14.

18)

EGUIDE22848

2018.11.15.

19)
Quality Indicator
EGUIDE48

28
2018.11.15.

20)

31
2018.11.30.

21)222019.12.1.
22) Miyanishi H, Uno K, Iwata M, Kikuchi Y, Ohi K, Hashimoto R, Sumiyoshi T, Nitta A:
Increase of methylation of DNA from blood on SHATI/NAT8L promotor site in the patientswith depression with no prior treatment.
92
2019.3.15.
(3)
1)

16

IGC

12COCORO

2018.12.8.
2)

16

IGC

12COCORO

2018.12.9.
3)30
2019.3.16.

4)30
2019.3.18.

(4)
1)

iPSB

2)

2018.10.3.
H30

AMED

2018.12.11.

1)Hashimoto R, Yasuda Y, Ohi K, Fukunaga M: Cross disorder analysis of brain measures:
implication of new diagnosis. Laboratory Seminar, Imaging Genetics Center, University ofSouthern California, Los Angeles, 2018.8.16.

2)

Hashimoto R, Yasuda Y, Ohi K, Fukunaga M: Cross disorder analysis of brain measures:
implication of new diagnosis. UCI Medical Center Grand Rounds, Irvine, 2018.8.15.

3)Hashimoto R, Yasuda Y, Ohi K, Fukunaga M: Cross disorder analysis of brain measures:
109

32

implication of new diagnosis. Luncheon Seminar, Atlanta, 2018.8.13.
4)

5

NCNP

2018.8.24.
5)
2018.8.30.
6)2018

2018.9.17.

7)
2018.11.10.
8)

YPS
2018.11.29.

9)
2019.1.12.
10)

1
2019.1.26.

11)
2019.1.31.

(1)
(2)
1)

2)

PCN

3)
4)
5)
6)
7)
(3)
1)

15
in

2018.7.14.

2)
40

6

2018.9.6.

3)

40

6

2018.9.6.
4)

4
65)

3
2018.9.8.
11040
2018.9.7.

40

66)

2

22

2018.12.2.
(4)
1)

Psychiatry and Clinical Neuroscience2)

Neuropsychopharmacology Reports

(1)
1)

in2)

15

2018.7.14.

EGUIDE2018.7.29.
3)

EGUIDE2018.10.6.

4)

EGUIDE

5)

EGUIDE2018.10.7.

2018.10.7.
6)
7)

EGUIDE2018.10.8.

EGUIDE2018.10.13.

8)

EGUIDE

9)2018.10.14.
EGUIDE2018.10.20.

10)

EGUIDE11)

2018.10.21.
EGUIDE2018.10.21.

12)

EGUIDE13)

2018.10.28.
EGUIDE2018.10.28.

14)

EGUIDE2018.11.3.

15)

EGUIDE

16)

EGUIDE2018.11.10.
17)
EGUIDE
18)

EGUIDE

19)

2018.11.17.
EGUIDE

20)

EGUIDE21)

2018.11.18.
EGUIDE2018.11.4.

2018.11.11.

20018.11.18.

2018.11.23.
111

3222)EGUIDE

23)

EGUIDE2018.11.24.

2018.11.25.
24)

EGUIDE2018.12.15.

25)

EGUIDE26)

2018.12.16.
EGUIDE2018.12.22.

27)

EGUIDE2018.12.23.

(2)
1)

15in2).

2018.7.14.
30

2018.7.28.
3)

15

EGUIDE-2018.7.29.
4)
2018.10.1.
5)

EGUIDE2018.10.13.

6)

EGUIDE2018.10.13.

7)

EGUIDE2018.10.14.

8)

EGUIDE2018.10.14.

9)

EGUIDE2018.11.10.

10)

EGUIDE2018.11.10.

11)

EGUIDE2018.11.11.

12)

EGUIDE2018.11.11.

13)

2848

14)

EGUIDE2018.11.16.
2018.11.17.
15)

EGUIDE2018.11.17.

16)

EGUIDE2018.11.18.

17)

EGUIDE112

2018.11.18.
18)

EGUIDE2018.11.23.

19)

EGUIDE2018.11.23.

20)

EGUIDE2018.11.24.

21)

EGUIDE2018.11.24.

1)

16

2)

IGC

12

COCORO2018.12.8-9.
EGUIDE2018.10.13.
3)

EGUIDE2018.10.14.

4)

EGUIDE2018.11.10.

5)

EGUIDE2018.11.11.

6)

EGUIDE2018.11.17.

7)

EGUIDE2018.11.18.

8)

EGUIDE2018.11.23.

9)

EGUIDE2018.11.24.

113